Initial Therapy with REQUIP

Initial therapy with REQUIP is effective in maintaining activities of daily living in early Parkinson’s disease patients. Rascol et al compared the risk of dyskinesia associated with REQUIP to L-dopa in patients with early Parkinson’s disease. The efficacy of initial therapy with REQUIP is comparable to L-dopa, while significantly reducing the risk of dyskinesia. Dyskinesia was almost 3 times lower in patients receiving REQUIP versus L-dopa, in initial therapy with REQUIP.¹

Reduce the risk of dyskinesia vs L-dopa. Prescribe REQUIP as initial monotherapy to delay the onset of dyskinesia.¹

Prescribing initial monotherapy with REQUIP delayed the need for L-dopa for an average (median) duration of 3 years.⁶

†Data from a subset analysis of a 5-year, double-blind, multicenter, randomized trial with REQUIP vs L-dopa in patients with early PD (Hoehn & Yahr stage I-III at baseline). Excludes 3 patients (1 L-dopa, 2 REQUIP) with baseline dyskinesia.

Allow patients to continue performing daily activities. Prescribe REQUIP as initial monotherapy to maintain patients’ ability to perform activities of daily living.¹